Soliris,
a drug distributed to treat rare disorders like Hemolytic-uremic syndrome and
Paroxysmal nocturnal hemoglobinuria is currently being manufactured and
developed by Alexion Pharmaceuticals.
The
company is the only manufacturer of approved drugs for the two ultra-rare
disorder that is life threatening and is the result of a genetic disorder. They
are involved in various researches on the immune system while focusing on how
it can be stopped from attacking healthy tissues.
Alexion is publicly traded on NASDAQ under the name ALXN and has been listed as No. 2
in Forbes’ World’s Most Innovative Companies. The sales of the company
plummeted in 2012 mainly because of acquisition projects. They spent a huge amount
of their sales in acquiring Enobia Pharma Corp. (Enobia) in February 7, 2012.
The following day, they also acquired patents and assets from Orphatec
Pharmaceuticals GmbH (Orphatec). On that same year as well, they spent on
Asfotase alfa, another acquired asset.
Currently,
the company employs a total of 1,373 employees and has been reportedly
generating revenue of $1.13 billion. Their headquarters is in Cheshire,
Connecticut.